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CpG motifs within phosphorothioate (PS)-modified
DNA drive Toll-like receptor 9 (TLR9) activation, but
the rules governing recognition of natural phospho-
diester (PD) DNA are less understood. Here, we
showed that the sugar backbone determined DNA
recognition by TLR9. Homopolymeric, base-free PD
20 deoxyribose acted as a basal TLR9 agonist as it
bound to and activated TLR9. This effect was
enhanced by DNA bases, even short of CpG motifs.
In contrast, PS-modified 20 deoxyribose homopoly-
mers acted as TLR9 and TLR7 antagonists. They
displayed high affinity to both TLRs and did not acti-
vate on their own, but they competitively inhibited
ligand-TLR interaction and activation. Although addi-
tion of random DNA bases to the PS 20 deoxyribose
backbone did not alter these effects, CpG motifs
transformed TLR9-inhibitory to robust TLR9-stimula-
tory activity. Our results identified the PD 20 deoxyri-
bose backbone as an important determinant of TLR9
activation by natural DNA, restrict CpG-motif depen-
dency of TLR9 activation to synthetic PS-modified
ligands, and define PS-modified 20 deoxyribose as
a prime effector of TLR9 and TLR7 inhibition.
INTRODUCTION
Toll-like receptors (TLRs) are a familyof nonclonal pattern-recogni-
tion receptors that recognize conserved pathogen-associated
molecular patterns (PAMPs). Under homeostatic conditions,
TLRs discriminate ‘‘non-self’’ from ‘‘self’’ in that they do not sense
host-derived ‘‘self-molecules’’ but become activated by PAMPs
during infection (Akira et al., 2006; Janeway and Medzhitov,
2002). Inmammals,distinct TLRs recognize PAMPs present onnu-
cleic acids, carbohydrates, lipids, and proteins (Akira et al., 2006;
Beutler et al., 2006). Although the majority of TLRs (TLR1, TLR2,
TLR4, TLR5, TLR6, and TLR11) are expressed at the cell surface,
the TLRs that recognize nucleic acids, i.e., TLR3 (sensing dou-
ble-stranded RNA [dsRNA] [Alexopoulou et al., 2001]), TLR7 and
TLR8 (sensing single-stranded RNA [ssRNA] [Diebold et al.,2004; Heil et al., 2004]), and TLR9 (sensing single-stranded CpG-
DNA [Hemmi et al., 2000]), are confined to intracellular compart-
ments inwhich they reside inendosomes (Akiraetal., 2006; Beutler
et al., 2006). Ligand binding by TLR3, TLR7, TLR8, and TLR9
occurs in the acidic environment of the endosome (Hacker et al.,
1998; Leifer et al., 2004) and causes cellular activation presumably
by stabilizing preformed TLR dimers or inducing TLR-dimer forma-
tion (Kindrachuk et al., 2007; Latz et al., 2007; Weber et al., 2003).
Species specificity of and sequence requirements for the
activation of TLR9 by ssDNA (Bauer et al., 2001; Krieg, 2002)
have primarily been elucidated with synthetic oligodeoxynucleo-
tides (ODNs) with a phosphorothioate (PS)-modified backbone
(see Figure S1A available online) to improve nuclease resistance
(Krieg, 2002) and cellular uptake (Sester et al., 2000). Optimal
CpG motifs for murine TLR9 activation were thus defined as
a nonmethylated CpG dinucleotide flanked by two 50 purines
and two 30 pyrimidines. Given that cytosine methylation or inver-
sion of CpG dinucleotides to GpC predominantly abolishes the
ability of PS ODNs to activate TLR9 (Krieg, 2002), the paradigm
has evolved that discrimination of ‘‘self-DNA’’ versus pathogen-
derived ‘‘non-self-DNA’’ relies on such CpG motifs (PAMPs),
which are abundant in pathogen-derived DNA but scarce in
mammalian ‘‘self-DNA’’ (Bird, 1986). Ligand-binding studies,
however, have yielded contradictory results with respect to the
ability of TLR9 to selectively bind ssDNA in a sequence-specific
manner (Latz et al., 2004; Yasuda et al., 2006). Furthermore, B
cells and dendritic cells (DCs) sense ‘‘self-DNA’’ via TLR9 upon
anti-DNA autoantibody-mediated DNA entry into the endolyso-
somal compartment (Boule et al., 2004; Leadbetter et al.,
2002). In addition, enforced endosomal translocation of verte-
brate DNA in complex with the antimicrobial peptide LL37 or
with the cationic lipid N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethy-
lammonium propan methylsulfate (DOTAP) induces TLR9 activa-
tion (Lande et al., 2007; Yasuda et al., 2006; Yasuda et al., 2005).
Altogether, these findings suggest that the endosomal localiza-
tion of TLR9 prevents constant activation by ‘‘self-DNA’’ under
homeostatic conditions. Along these lines, there is evidence
that a hybrid TLR composed of the extracellular domain of
TLR9 (TLR9-ect) and the cytoplasmic and transmembrane
domains of TLR4, which was reported to localize to the cell sur-
face, recognizes mammalian DNA (Barton et al., 2006), even
though these findings are controversial (Leifer et al., 2006). We
therefore envisioned two possible scenarios for the activation
of TLR9 by ‘‘self-DNA’’: Either CpG motifs in mammalian DNAImmunity 28, 315–323, March 2008 ª2008 Elsevier Inc. 315
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a phosphodiester (PD) backbone has an inherent, sequence-
independent stimulatory capacity, a quality that may have
been obscured in experiments using PS-modified DNA. Conse-
quently, we asked whether different rules apply for TLR9 activa-
tion by natural PD versus PS-modified DNA. Here, we describe
that the DNA sugar backbone 20 deoxyribose represents a prime
determinant for ssDNA-TLR9 interactions. In its natural PD
version, base-free 20 deoxyribose homopolymers act as basal
TLR9 agonists, and DNA bases, even short of CpG motifs,
enhance agonist activity. In their PS-modified version, however,
20 deoxyribose homopolymers act as TLR9 and TLR7 antago-
nists. Random bases do not alter antagonist function, but DNA
sequences containing CpG motifs transform TLR9-inhibitory to
robust TLR9-stimulatory activity.
Thus, we have shown that TLR9 senses natural, unmodified
ssDNA present in the endosome in a CpG-independent manner,
on the basis of the inherent stimulatory potential of the PD 20
deoxyribose backbone. The DNA sequence can modulate the
strength of the response, but strict CpG-motif dependency of
TLR9 activation is an exclusive characteristic of PS-modified
ssDNA, which otherwise is a TLR9 and TLR7 antagonist.
RESULTS
30 Poly-G Extension Reveals TLR9 Agonist Activity
of PD Non-CpG DNA
On the basis of reports that, similar to cationic lipids, 30 extension
of PD ODNs with polyguanosine (poly-G) tails not only protects
Figure 1. CpG-Independent TLR9 Activa-
tion by Natural PD ODNs
(A and B) WT or Tlr9/ Flt3L-DCs (1 3 106/well)
were incubated for 18 hr with 3 mM ODNs, ODNs
30 extended with 24Gs, or ODNs complexed to
DOTAP. IL-6 (A) and IFN-a (B) concentrations
were detected in culture supernatants by
enzyme-linked immunosorbant assay.
(C and D) WT Flt3L-DCs (1 3 106/well) were incu-
bated for 18 hr with indicated concentrations of
ODNs alone or ODNs 30 extended with 24Gs (C)
and ODNs alone or ODNs complexed to DOTAP
(D). IL-6 concentrations were detected in culture
supernatants by enzyme-linked immunosorbant
assay. Values for PD 1668 and PD non-CpG
AP-1 in (C) and (D) are taken from the same set
of experiments. Mean values and standard devia-
tions of three independent experiments are shown
in (A)–(D).
against DNase degradation (Bishop et al.,
1996) but also drives enhanced endoso-
mal translocation (Dalpke et al., 2002),
we first tested whether the poor TLR9
activation by single-stranded PD CpG
ODNs can be improved by 30 PD poly-G
extension. CpG ODNs are commonly
classified into A or B type according to
their potential to preferentially induce
TLR9-dependent interferon-a (IFN-a)
production or proinflammatory cytokine
production and DC maturation, respectively (Verthelyi et al.,
2001; Krieg, 2002). We observed enhanced cellular uptake
(Figure S2A) and cytokine production (Figure S2B) by Flt3L-
DCs (containing a mixture of plasmacytoid [p] DCs and myeloid
[m] DCs) upon 30 PD poly-G extension of B type PD CpG ODN
1668 (CpG-B), depending on the length of the poly-G tail (for se-
quences and chemical structures, see Figure S1). Of note, 30 PD
poly-G extension (24 Gs) not only improved the poor TLR9-stim-
ulatory potential of DNase-sensitive PD CpG-B but also recon-
stituted it, at high concentrations, to values similar to canonical
PS CpG-B (Figure S2B; see Figure 1C for titration). It also con-
veyed TLR9-dependent IFN-a-inducing activity (Figure S2C), to
date considered a sequence-specific hallmark of A type CpG
(CpG-A) (Kerkmann et al., 2005; Verthelyi et al., 2001).
We speculated that enhanced endosomal translocation
through 30 PD poly-G extension may also lead to TLR9 activation
by PD ODNs devoid of canonical unmethylated CpG-motifs (PD
non-CpG ODNs). Indeed, upon 30 PD poly-G extension (24 Gs),
both methylated PD CpG-B and PD ODNs lacking canonical
CpG motifs (e.g., PD non-CpG ODN AP-1 and PD non-CpG
ODN pTC; Figure S1B) triggered TLR9-dependent IL-6 and
IFN-a production (Figures 1A and 1B) as well as upregulation
of CD86 costimulatory molecules (Figure S2D) by Flt3L-DCs.
Across a wide range of ODN concentrations, the TLR9-activating
potential of 30 poly-G extended PD ODNs was similar to that of
PD ODNs complexed to N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethy-
lammonium propan methylsulfate (DOTAP) (Figures 1C and 1D;
Figure S2E). These results imply that the previously reported
TLR9-stimulatory potential of PD non-CpG single-stranded316 Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc.
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a transfection-agent-related phenomenon but rather reflects
the ability of TLR9 to recognize and react to unmodified PD
ODNs short of canonical CpG-motifs. In contrast, PS-modified
ODNs lacking CpG-motifs did not activate TLR9, even when
complexed to DOTAP or 30 extended by poly-Gs (Figures 1A,
1B, and 1D; Figure S2E).
To exclude the possibility that the data on TLR9 activation by
endosomally translocated PD non-CpG ODN AP-1 may have
been biased by the CG dinucleotide present in the AP-1
sequence (Although it does not qualify as a canonical CpG motif,
noncomplexed PS or PD non-CpG ODN AP-1 is therefore TLR9
‘‘inactive.’’), we repeated this set of experiments with non-CpG
ODN AP-1 molecules that had the CG dinucleotide eliminated
by substituting A for C. No relevant differences in the TLR9-stim-
ulatory potential were seen when compared to the original
non-CpG ODN AP-1 sequence (data not shown).
Poly-G-extended PD ODN sequences efficiently form G-tet-
rads and are preferentially retained in early endosomes (data
not shown). We have shown that both 30 PD poly-G-extended
or DOTAP-complexed PD CpG ODN and PD non-CpG ODN
induce IFN-a production (Figure 1B and Figure S2E), the latter
with lower efficiency. Our data thus support the notion that PD
ODN multimerization is sufficient for sequence-independent
IFN-a induction (Guiducci et al., 2006; Honda et al., 2005) at
optimal ligand concentrations because it leads to enhanced
cellular uptake and early endosomal retention and thus to
ligand-induced activation of the TLR9-MyD88-IRF-7 signaling
pathway. Indeed, IFN-a production was completely abolished
in TLR9- (Figure 1B), MyD88- (not shown), and IRF-7-deficient
cells (Figure S3A). When pDCs and mDCs were sorted from
mixed Flt-3L DC cultures, IFN-a was found to be exclusively
produced by pDCs, whereas the main source of proinflammatory
cytokines such as IL-6 were mDCs (Figure S3B). Overall, IFN-a
induction by multimerized PD ODNs relied on mechanisms sim-
ilar to those previously defined for canonical CpG-A.
The PD Sugar Backbone Licenses DNA
for TLR9 Activation
Certain PS modified non-CpG ODN sequences, including those
containing a GGGG motif (immunoregulatory sequences [IRSs]),
have been described to inhibit ligand-driven TLR9 and/or TLR7
activation in a sequence-dependent manner (Barrat et al.,
2005; Duramad et al., 2005; Gursel et al., 2003). When we
used the TLR9-relevant IRS ODN sequences 869 and 954 (Barrat
et al., 2005) with a natural PD sugar backbone and complexed
them to DOTAP, they actually activated DCs to produce IL-6
(Figure 2A) and IFN-a in a TLR9-dependent manner (data not
shown). Because changing the IRS backbone from PS to PD
converted TLR9 inhibition into TLR9 stimulation, the importance
of the DNA sugar backbone for the interaction between DNA and
TLR9 became apparent. This conclusion was supported by the
observation that the TLR9-stimulatory activity of PD non-CpG
ODN AP-1 complexed to DOTAP was abolished in a hybrid PD
AP-1 in which the DNA-backbone sugar 20 deoxyribose was
replaced by the RNA sugar ribose (ribose-AP-1; Figure 2B and
Figure S4A). Similar results were obtained when PD poly-G-
extended PD ODN AP-1 was compared to PD poly-G-extended
PD ribose-AP-1 (data not shown). In terms of TLR9 activation,dominance of the sugar backbone over the nucleic-acid base
component of ODNs was also observed with a hybrid containing
a canonical CpG motif, ribose 1668 (Figure 2C and Figure S4B).
Thus, otherwise stimulatory ssDNA is not recognized by TLR9
when the DNA-backbone sugar 20 deoxyribose is replaced with
the RNA-backbone sugar ribose, irrespective of its base
sequence. However, both ribose AP-1 and ribose 1668 triggered
minimal but marked TLR7 activation, whereas 2-o-methyl-mod-
ified ribose AP-1 did not (Figures 2B and 2C; Figures S4A and
S4B), indicating a ribose-backbone-instructed, sequence-inde-
pendent activation mode of TLR7. In context, when the DNA-
backbone sugar PD 20 deoxyribose was present, it rendered
TLR9 permissive even for nucleic-acid bases usually not present
in natural DNA, because a hybrid 20-mer combining a PD 20
deoxyribose backbone with aligned uracil bases (poly-U-20
deoxyribose; see Figure S1A) activated both TLR9 and TLR7.
Tlr7/ or Tlr9/ cells both showed activation, whereas
Myd88/ and Tlr7/ Tlr9/ cells were each unresponsive
(Figure 2D; Figure S4C and data not shown). These data show
that TLR9 strictly requires 20 deoxyribose, which licenses
ODNs for activation even in the absence of typical DNA bases.
In contrast, TLR7 is more liberal with respect to backbone
restrictions, because both ribose and 20 deoxyribose backbones
were accepted for activation.
PD 20 Deoxyribose Homopolymers Act as TLR9 Agonists
The findings described above suggested a dominant role of PD
20 deoxyribose in TLR9-mediated DNA recognition. We therefore
Figure 2. Role of the Sugar Backbone in TLR9 and TLR7 Activation
(A) WT Flt3L-DCs (13 106/well) were incubated for 18 hr with 3 mM of PD ODNs
alone or PD ODNs complexed to DOTAP. IL-6 concentrations were detected in
culture supernatants by enzyme-linked immunosorbant assay.
(B and C) WT, Tlr9/ or Tlr7/ Flt3L-DCs (1 3 106/well) were incubated for
18 hr with 3 mM of indicated PD ODN or hybrid DNA/RNA molecules com-
plexed to DOTAP. IL-6 concentrations were detected in culture supernatants
by enzyme-linked immunosorbant assay.
(D) WT, Tlr9/, Tlr7/, or Myd88/ Flt3L-DCs (13 106/well) were incubated
for 18 hr with 3 mM of PD ODNs or PD poly-U-20 deoxyribose complexed to
DOTAP. IL-6 concentrations were detected in culture supernatants by
enzyme-linked immunosorbant assay. Mean values and standard deviations
of three independent experiments are shown in (A)–(D).Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc. 317
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DNA Sugar Backbone Determines TLR9 ActivationFigure 3. PD 20 Deoxyribose Homopolymer Is a TLR9 Agonist
(A) WT or Tlr9/ Flt3L-DCs (13 106/well) were incubated for 18 hr with 3 mM of indicated ODN (20-mer), PD 20 deoxyribose (20-mer), or controls, all complexed to
DOTAP. IL-6 concentrations were detected in culture supernatants by enzyme-linked immunosorbant assay. Mean values and standard deviations of at least
three independent experiments are shown.
(B) SPR analysis of 100 nM mTLR9-ect binding to biotinylated ODN or sugar-backbone molecules immobilized at equimolar amounts on a streptavidin-coated
biosensor chip. mTLR2-ect was used as a control. No mTLR2-ect binding to any of the ODNs or sugar-backbone molecules was detected.analyzed whether PD 20 deoxyribose (20-mer, base free) itself
activated TLR9. Although 30 poly-G-extended PD 20 deoxyribose
homopolymers failed to activate TLR9 (not shown), PD 20 deoxy-
ribose homopolymers complexed to DOTAP caused low but
substantial TLR9-dependent cell activation (Figure 3A and
Figure S4D). No stimulatory activity was observed with 20 deoxy-
ribose-5-phosphate monomers, PD C3 spacer (20-mer; 20 de-
oxyribose replaced by three linear C atoms, conserving the dis-
tance between linking phosphodiester groups; see Figure S1A),
PS-modified 20 deoxyribose (20-mer), or PD or PS ribose
(20-mer); each complexed to DOTAP (Figure 3A). These data
suggested that base-free PD 20 deoxyribose homopolymers
act as agonists for TLR9.
To strengthen our confidence in the ability of the base-free PD
DNA sugar backbone to activate TLR9, we determined whether
PD 20 deoxyribose (20-mer) directly binds to TLR9. Surface
plasmon resonance (SPR) analysis at acidic pH revealed robust
binding of PD CpG-B ODN 1668 and intermediate binding of PD
non-CpG ODN AP-1 to the ectodomain of murine TLR9 (mTLR9-
ect) but not to that of TLR2 (mTLR2-ect) (Figure 3B), whereas
base-free PD 20 deoxyribose homopolymers displayed low, but
marked, specific binding to mTLR9-ect; PD C3 spacer and PD
ribose homopolymers were both negative. These data corrobo-
rated the finding that PD 20 deoxyribose homopolymers act as
TLR9 agonists and also explained why the ribose substitution
within an ODN sugar backbone abrogated TLR9 activity (Figures
2B and 2C; Figures S4A and S4B).
PS-Modified 20 Deoxyribose Homopolymers Bind
to TLR9 and TLR7 with High Affinity
In order to evaluate the role of the PS modification in DNA-TLR9
interactions, we resorted to a luminescent-proximity assay
(AlphaScreen) based on the transfer of singlet oxygen between
closely opposed donor and acceptor molecules (Latz et al.,
2007). In this system, we again observed marked, dose-depen-
dent, and specific binding of stimulatory PD 20 deoxyribose ho-
mopolymers yet enhanced binding of PD non-CpG ODN AP-1
and of PD CpG-B ODN 1668 to the ectodomain of TLR9 (human;
hTLR9-ect). PD C3 spacer and both PD and PS ribose homopol-
ymers did not bind to hTLR9. Interestingly, the affinity of nonsti-318 Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc.mulatory base-free PS 20 deoxyribose homopolymers to hTLR9
was approximately two orders of magnitude higher than that of
PD 20 deoxyribose homopolymers (Figure 4A). Of note, both PD
and PS 20 deoxyribose homopolymers also bound to hTLR7-ect
with affinities similar to those defined for hTLR9-ect, in that PD 20
deoxyribose showed low but marked hTLR7-ect affinity and PS
20 deoxyribose showed high hTLR7-ect affinity (Figure 4B). In
addition, PD ODNs (PD CpG-B ODN 1668 and PD non-CpG
ODN AP-1) showed intermediate hTLR7-ect affinity, also com-
parable to their affinity to hTLR9-ect (data not shown). PD and
PS ribose, in contrast, displayed specific, low-affine binding
only to hTLR7-ect but not to hTLR9-ect (Figure 4C). The finding
that the DNA-backbone sugar PD 20 deoxyribose binds both to
TLR9 and TLR7 complements our functional data on TLR7 acti-
vation by PD poly-uracil 20 deoxyribose (Figure 2D). Furthermore,
the selective affinity of TLR7 (but not of TLR9) to the RNA sugar
backbone ribose (PD or PS) allows for a ribose-backbone-
instructed activation of TLR7 as seen with thymidine, but not ura-
cil, containing ribose AP-1 and ribose 1668 hybrids (Figures 2B
and 2C). Finally, both TLR7 and TLR9 appear permissive for
atypical bases (thymidine and uracil, respectively), yet only
TLR7 is liberal with respect to the nucleotide backbone, in that
TLR7 accepts both PD ribose and PD 20 deoxyribose backbones
for binding and activation.
PS-Modified 20 Deoxyribose Homopolymers
Act as TLR9 and TLR7 Antagonists
The observation that nonactivating PS 20 deoxyribose homopol-
ymers display high affinity to both TLR9 and TLR7 suggested
that they might function as competitive inhibitors of TLR9 and
TLR7 activation. In support, plasmon-resonance analysis
revealed dose-dependent inhibition of PD CpG-B ODN binding
to mTLR9-ect by PS 20 deoxyribose (20-mer) (Figure 5A). PS 20
deoxyribose linking random bases (e.g., PS non-CpG ODN
AP-1; Figure S5A) and PS IRS ODN 869 (Figure S5B) displayed
similar inhibition. In contrast, PD 20 deoxyribose homopolymers
exhibited low competitive effects only at very high concentra-
tions, consistent with their comparatively low affinity to TLR9
(Figure 5B). On a functional level, base-free PS 20 deoxyribose
homopolymers dose-dependently inhibited PD CpG-B-induced
Immunity
DNA Sugar Backbone Determines TLR9 ActivationTLR9-mediated cytokine responses in vitro (Figures 6A and 6B)
and in vivo (Figure 6C). Again, PS IRS ODN 869 or 954 (Fig-
ure 6B) or random-base PS non-CpG ODN AP-1 (Figure S5C)
manifested comparable inhibition. Interestingly, the DNA sugar
backbone PS 20 deoxyribose also inhibited PD RNA (20-mer; oli-
goribonucleotide [ORN] AP-1)-mediated (Figure 6D) or R848-
mediated TLR7 activation in DCs, as did PS non-CpG ODN
AP-1 or even PS CpG-B ODN (data not shown), similar to
TLR7-inhibitory PS IRS ODN 661 (Barrat et al., 2005). Of note,
inhibition of ligand-induced TLR9 and TLR7 activation by PS-
modified 20 deoxyribose homopolymers or PS ODN was TLR
specific because TLR3 activation by poly I:C, TLR2 activation
Figure 4. PS 20 Deoxyribose Homopolymer Displays High Affinity
to TLR9 and TLR7
(A–C) AlphaScreen (homogenous ligand-binding assay) assessment of hTLR9-
ect (A and C) and hTLR7-ect (B and C) binding to biotinylated ODNs or sugar-
backbone molecules. hTLR2-ect was used as a control. No hTLR2-ect binding
to any of the ODNs or sugar-backbone molecules was detected.by Pam3Cys, and TLR4 activation by LPS were all unaffected
(data not shown).
With allowance for sequence-specific modulatory effects
(Barrat et al., 2005), these data imply that the PS-modified 20
deoxyribose backbone represents the dominant determinant of
competitive TLR9 and TLR7 inhibition by inhibitory PS ODNs.
Importantly, though, the TLR9-inhibitory quality of PS ODNs is
overcome in the presence of a canonical CpG motif because
PS CpG ODN successfully convert the high TLR9 affinity of
a PS-modified molecule into robust TLR9-activation (Figures
1A and 1C; Figure S2B).
DISCUSSION
Our results uncover a previously unappreciated role of the DNA
sugar backbone 20 deoxyribose in ssDNA recognition by TLR9.
In its natural PD form, the base-free 20 deoxyribose backbone
binds to TLR9 with low affinity and provides basal activation
upon enforced translocation into TLR9-positive endosomes.
Any DNA bases, and in particular CpG motifs, linked via the PD
sugar backbone, increases both TLR9 affinity and activation. In
quantitative terms, base-free PD 20 deoxyribose homopolymers
displayed 10% and PD non-CpG ODN displayed 60% of
the TLR9 activation potential of PD CpG-B ODNs, as read out
by IL-6.
These characteristics of PD ODNs differ from PS-modified
ODNs. PS-modified 20 deoxyribose homopolymers bind to
TLR9 and surprisingly also to TLR7 100-fold more strongly
than PD 20 deoxyribose homopolymers, lack stimulatory activity,
but competitively inhibit ligand-induced TLR9 and TLR7 stimula-
tion. Although random DNA bases do not affect the antagonist
activity of PS 20 deoxyribose, CpG motifs reverse this domi-
nant-negative effect on TLR9, translating high PS ODN TLR9
affinity into strong TLR9 stimulation. Our data do not provide
an answer as to how this CpG-dependent effect is brought about
on a mechanistic level; we believe that the crystal structure of
TLR9, once available, may provide a solution. The stimulatory
power of PS CpG-B ODNs turns out to be 10-fold greater
than that of PD CpG-B ODNs, most likely due to high TLR9 affin-
ity together with high stability against endosomal DNases. As
a consequence, even very low extracellular concentrations of
PS CpG-B ODNs lead to robust stimulation of endosomal
TLR9. Overall, these data imply that both the strict CpG-motif
dependency as well as the remarkably high TLR9 affinity are
exclusive characteristics of PS-modified ODNs, which represent
promising immunopharmacons (PS CpG-B [Krieg, 2002], PS IRS
[Barrat et al., 2005], etc.) but do not faithfully mimic the interac-
tion of natural PD ODNs with TLR9.
Given that TLRs that recognize nucleic acids (TLR3, TLR7,
TLR8, and TLR9) are located in endosomes (Akira et al., 2006;
Beutler et al., 2006), it is likely that both the endosomal concen-
tration as well as the respective TLR9 affinity of DNA ligands will
influence the TLR9 response. Because uptake of natural PD
ODN by immune cells is poor (Krieg, 2002; Sester et al., 2000),
we used G-tetrad-mediated multimerization of single-stranded
PD ODN by 30 poly-G extension or complex formation with
DOTAP to increase DNase resistance and enhance cellular up-
take. Upon multimerization or complex formation, we observed
robust endosomal translocation of PD 20 deoxyriboseImmunity 28, 315–323, March 2008 ª2008 Elsevier Inc. 319
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DNA Sugar Backbone Determines TLR9 ActivationFigure 5. PS 20 Deoxyribose Homopolymer Is a Competitive Inhibitor of TLR9 Ligand Binding
(A and B) SPR analysis of 200 nM mTLR9-ect binding to biotinylated PD CpG-B 1668 immobilized on a streptavidin-coated biosensor chip in the presence or
absence of different concentrations of competing PS (A) or PD (B) 20 deoxyribose (20-mer).homopolymers and PD ODNs similar in magnitude to that of PS
ODN. This allowed us to compare the TLR9 immunobiology of
natural PD versus modified-PS ODNs under almost normalized
endosomal concentrations. These conditions revealed the
TLR9-stimulatory potential of base-free PD 20 deoxyribose ho-
mopolymers and of natural PD non-CpG ODNs in plasmacytoid
(p) DC- and myeloid (m) DC-containing Flt3L-cultured bone-mar-
Figure 6. PS 20 Deoxyribose Homopolymer Is a TLR9 and TLR7
Antagonist
(A) WT Flt3L-DCs (13 106/well) were incubated for 18 hr with 2 mM stimulatory
PD CpG-B ODN ± indicated concentrations of PS or PD 20 deoxyribose back-
bone molecules. IL-6 concentrations were detected in culture supernatants by
enzyme-linked immunosorbant assay.
(B) WT Flt3L-DCs (13 106/well) were incubated for 18 hr with 2 mM stimulatory
PD CpG-B ODN ± indicated concentrations of PS 20 deoxyribose (20-mer) or
PS IRS ODNs. IL-6 concentrations were detected in culture supernatants by
enzyme-linked immunosorbant assay. Portions of this graph are from the
same set of experiments as in (A).
(C) C57BL6 WT mice were injected i.v. with 2.5 nmol PD CpG-B ODNs ± indi-
cated amounts of PS or PD 20 deoxyribose (20-mer), all complexed to DOTAP.
Blood samples were obtained 2 hr after injection. Serum IL-6 concentrations
were detected by enzyme-linked immunosorbant assay.
(D) WT Flt3L-DCs (13 106/well) were incubated for 18 hr with 0.5 mM of TLR7-
stimulatory PD RNA (ORN AP-1) complexed to DOTAP. Indicated concentra-
tions of PS or PD 20 deoxyribose (20-mer) had been added to the culture 15 min
prior to stimulation. IL-6 concentrations were detected in culture supernatants
by enzyme-linked immunosorbant assay. Mean values and standard devia-
tions of three independent experiments are shown in (A)–(D).320 Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc.row cells. TLR9 activation in mDCs occurs in late endosomes
and causes production of proinflammatory cytokines, whereas
IFN-a induction in pDCs depends on retention of multimerized
ODN ligands in TLR9-positive early endosomes (Guiducci
et al., 2006; Honda et al., 2005). Although enhanced ODN uptake
and, consequently, increased endosomal ligand concentrations
are clearly responsible for the TLR9-dependent cytokine induc-
tion by PD non-CpG ODNs in myeloid DCs, poly-G- or DO-
TAP-mediated complex formation both have an additional effect
that allows induction of a-interferon production in plasmacytoid
DCs, i.e., temporal retention of ODN ligands in early endosomal
compartments. Complexed PD non-CpG ODNs thus induce
IFN-a production in pDCs because of increased ligand concen-
trations in early endosomes. Importantly, none of the above
mentioned stimulatory effects were seen in Tlr9/ cells, sug-
gesting that cytosolic DNA sensors do not participate in ODN
recognition. We conclude that not only CpG ODNs but also PD
non-CpG ODNs can trigger robust TLR9 activation in both
pDCs and cDCs upon enforced endosomal translocation. Our
data thus help to explain why natural ‘‘self-DNA’’ poor in unme-
thylated CpG motifs can drive TLR9 activation.
PS-based IRS ODN 865 and 661 have been reported to block
TLR9 or TLR7 activation in a sequence-dependent manner,
respectively (Barrat et al., 2005). Analyzing ligand affinities of
TLR9 and TLR7 with a recently described luminescent-proximity
assay (AlpaScreen [Latz et al., 2007]), we demonstrated high-
affine binding of PS 20 deoxyribose (20-mer) to TLR9 and TLR7
but did not detect agonist function. Instead, base-free PS 20
deoxyribose efficiently inhibited ligand-driven TLR9 and TLR7
activation, as did PS-modified ODN lacking CpG motifs. These
findings suggest that the PS 20 deoxyribose backbone within
PS-modified ODNs lacking CpG motifs is an important mediator
of TLR9 and TLR7 antagonism. Obviously, in IRS ODNs, certain
DNA bases bias the inhibitory effect of PS 20 deoxyribose either
toward TLR9 or TLR7 inhibition. In fact, similar to PS IRS ODNs,
PS 20 deoxyribose homopolymers may manifest therapeutic
potential as immunopharmacons for ablation of TLR9 and/or
TLR7 activation in certain autoimmune diseases such as lupus
erythematosus (Barrat et al., 2005) or psoriasis (Lande et al.,
2007). Analysis of animal models that mimic human autoimmune
diseases will help to answer this question.
Compared to TLR9, ligand interaction and activation of TLR7
appear to follow different rules. Although we found ribose-back-
bone-instructed TLR7 activation through base-bearing, non-
uracil ribose molecules (ribose-AP-1; ribose 1668), no inherent
Immunity
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detected, despite specific binding of the base-free ribose back-
bone to TLR7. In contrast to TLR9, shown here to be 20 deoxyri-
bose sugar backbone-specific, TLR7 activation does not strictly
depend on a ribose backbone because poly-U-20 deoxyribose
stimulated TLR7 (our data and Diebold et al., 2006). Moreover,
PS 20 deoxyribose efficiently inhibited ligand-induced TLR7
activation in vitro, as do TLR7-inhibiting PS IRS ODNs (Barrat
et al., 2005). These data complement the striking ability of
TLR7 to bind not only base-free ribose sugar backbones or
ORNs but also 20 deoxyribose sugar backbones or ODNs, with
affinities very similar to TLR9. Hence, nucleic-acid recognition
by TLR7 is not completely RNA sugar backbone specific.
In search of a mechanistic explanation for 20 deoxyribose
specificity of TLR9, we performed sequence and structure align-
ments with dsRNA-specific hTLR3, the only nucleotide-specific
TLR with a crystal structure available to date (Choe et al.,
2005). Overall, 27% of all amino acids (aa) are conserved
between hTLR3 and hTLR9, and protein domains are roughly
overlapping. The only hTLR3-ect residue that has been directly
linked to recognition of ribose-specific 20 OH groups is aspara-
gine N541 (Bell et al., 2006), which, in hTLR9, corresponds to
arginine (R639). mTLR9, instead of R639, possesses an R resi-
due in close proximity (R645). We propose that R is well suited
to differentially mediate 20 H but not 20 OH binding, first because
of steric constraints, with the R side chain occupying more space
than N, thus favoring 20 H instead of 20 OH entry into the binding
site. Second, R commonly binds phosphate anions because of
its positively charged guanidino group and is therefore often
found in the active binding site of phosphorylated substrate
binders. For firm conclusions, however, analysis of crystal struc-
tures of TLR9 binding either natural PD or PS-modified nucleic
acids will be essential.
Dimerization is a common theme in models of TLR activation
(Kindrachuk et al., 2007; Latz et al., 2007; Weber et al., 2003).
Induction of TLR9 activity has been shown to involve ligand-
induced conformational changes in constitutive TLR9 homo-
dimers, causing close approximation of cytoplasmic TIR
domains (Latz et al., 2007). On the basis of our data, we propose
that the low-affine PD DNA sugar backbone drives such confor-
mational changes in TLR9 homodimers, whereas separate
recognition of nucleic acids provides enhanced ligand-receptor
affinity and activation, possibly through a mechanism involving
intramolecular or intermolecular positive cooperativity. Perhaps
because of steric hindrance from the large sulfur atom, which
also creates a new chiral center, inhibitory PS 20 deoxyribose,
despite high TLR9 affinity, cannot induce such basic conforma-
tional changes in preformed TLR9 dimers, unless aided by CpG
motifs.
The DNA-methylation pattern differs between mammalian and
prokaryotic genes. It is believed that CpG motifs, mainly modi-
fied by methylation in the mammalian genome but abundant in
their unmethylated form in prokaryotic organisms, represent
a critical determinant for the mammalian immune system to
discriminate foreign invaders or pathogens from ‘‘self.’’ In accor-
dance with this concept, only unmethylated CpG motifs are
thought to drive TLR9 activation and thus act as PAMPs. Our
data challenge this view. We show that CpG-motif dependency
exclusively characterizes PS-modified ODNs, whereas PDODNs short of CpG motifs activate TLR9. Mechanistically, these
properties of natural PD ODNs versus PS-modified ODNs are
determined by the DNA sugar backbone 20 deoxyribose, which
per se acts as a TLR9 agonist (PD) or TLR9 antagonist (PS). It
therefore seems reasonable to propose that evolutionary
pressure has exiled DNA-recognizing TLR9 from the cell surface
to intracellular compartments to avoid activation by extracellular
host-derived DNA. Confined to endosomes, TLR9 is perfectly
positioned to alert the host to DNA from invading pathogens,




CpG-A ODNs (2216) was from Coley Pharmaceuticals. Other ODNs were com-
mercially synthesized by TIB Molbiol. PD and PS 20 deoxyribose 20-mer was
synthesized by IBA GmbH and TIB Molbiol. PD/PS ribose 20-mer (±50-FAM/
carboxyfluorescein succinimidyl ester; ±30-Biotin according to experimental
requirements), ORN AP-1, DNA/RNA hybrid molecules, and ODNs 50 labeled
with Cy3 or Cy5 were from IBA GmbH. 20 deoxyribose 5-phosphate monomer
was from Sigma-Aldrich.
Antibodies
a-mouse B220-PE and a-mouse CD86-PE antibodies were from BD Biosci-
ences. a-mouse 120G8 (-FITC or -Biotin) antibody (Asselin-Paturel et al.,
2003) was provided by A. Krug.
Mice
All mice were on C57BL6 genetic background. Male WT mice (Jackson), male
Tlr9/, Tlr7/ and Tlr7/ Tlr9/ mice (provided by S. Akira) and male Irf7/
mice (provided by T. Taniguchi) were bred at our SPF animal facility according
to German federal regulations and institutional guidelines.
Preparation of DC
Bone-marrow cells were harvested from mouse femurs and tibias and cultured
for 8 days in complete RPMI (RPMI 1640 with L-glutamine, heat-inactivated
10% FCS, 100 mg/ml streptomycin, and 50 mM 20 mercaptoethanol; all from
PAA Laboratories) conditioned with recombinant murine Flt3-ligand (WEHI).
Cell Sorting
Flt3L-DC subsets were highly enriched by FACS sorting (FACS Aria, BD
Biosciences) after staining with a-120G8-FITC (Asselin-Paturel et al., 2003)
and a-B220-PE antibodies. Discrimination between live and dead cells was
performed with propidium iodide (Invitrogen). The purity of the sorted cells
was controlled on a CyAn ADP Lx (Dako) and found to be >99%.
Cell Stimulation
Flt3L-DCs were suspended in 500 ml RPMI 1640 with 10% FCS and 50 mM 20
mercaptoethanol (all from PAA Laboratories) on 24-well plates and incubated
for indicated times at indicated concentrations with ODNs, hybrids, backbone
molecules, or controls. For measurement of cytokine induction, culture super-
natants were collected for analysis by enzyme-linked immunosorbant assay
(ELISA) specific for mouse IL-6 (BD Biosciences) and mouse IFN-a (compiled
from rat anti-mouse interferon-a antibody [Tebu-Bio], rabbit anti-mouse inter-
feron-a antibody [Tebu-Bio], POX-donkey anti-rabbit IgG antibody [Jackson]).
For analysis of surface markers, cells were harvested, washed 23 with
ice-cold PBS/3% FCS, incubated with a-CD86 PE antibody for 0.5 hr, washed
23, fixed with 2% paraformaldehyde, and analyzed by fluorescence-activated
cell sorting (FACS).
For complex formation with DOTAP (Roche), ODNs, hybrids, backbone
molecules, and controls were suspended in 50 ml Opti-Mem (Invitrogen),
combined with 50 ml DOTAP solution (10 mg in Opti-Mem), incubated for
15 min at room temperature, and added to cells.Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc. 321
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ODN uptake was measured as described (Roberts et al., 2005). In brief, 0.5 3
106 Flt3L-DC were incubated with Cy5-labeled ODNs for 45 min in 500 ml
complete RPMI. Harvested cells were washed with ice-cold PBS, incubated
with 12.5 mg/ml dextran sulfate (Sigma) for 10 min on ice (for removal of
ODN bound to the cell surface), washed in PBS, fixed with 2% paraformalde-
hyde, and analyzed by fluorescence-activated cell sorting (FACS).
I.V. Injection and Collection of Blood Samples
C57BL6 WT mice were injected with preprepared DOTAP complexes (30 ml
DOTAP at final volume of 200 ml in sterile PBS) of 2.5 nmol stimulatory PD
CpG-B-ODN 1668 alone or in combination with 0.5 nmol or 2.5 nmol 20 deoxy-
ribose backbone molecules (20-mers; PS or PD) into the tail vein. After 2 hr,
mice were sacrificed and blood samples were collected by intracardial punc-
ture. Samples were centrifuged after coagulation was complete. Serum was
used for analysis by enzyme-linked immunosorbant assay.
Human TLR-Fc Protein Purification
hTLR9-Fc protein was purified from lysates of HEK293 cells stably expressing
a fusion protein containing the ectodomain of human TLR9 linked to the Fc
portion of mouse IgG2a. Cells were grown in serum-free media (CD293, Invi-
trogen), harvested by centrifugation, washed twice in ice-cold PBS, and lysed
in lysis buffer on ice (1% CHAPS, 50 mM Tris-Cl, 150 mM NaCl, 1 mM EDTA,
10% glycerol, 12 mM 20 mercaptoethanol, and complete protease inhibitors
[Roche]). After pelleting nuclei at 14.000 3 g and 0.45 mm filtration of the
lysates (Sartobran 300, Sartorius), we captured the protein by protein A chro-
matography (Amersham) at 4C with automated FPLC. After extensive wash-
ing of the columns in lysis buffer, the protein was eluted by a continuous
gradient from pH 7.4 to pH 3 (low pH buffer: 50 mM citric acid [pH 3],
150 mM NaCl, 1 mM EDTA, 10% glycerol, and 12 mM 20 mercaptoethanol).
The low pH was neutralized by addition of one-tenth of the volume 1 M Tris-
Cl, pH 8 into each of the fractions. As a polishing step, purified hTLR9-Fc
was separated by size-exclusion chromatography (superose 6, Amersham),
and hTLR9-Fc containing fractions were pooled and concentrated. hTLR7-
Fc and hTLR2-Fc proteins were purified as above. Here, the cells stably
expressed a fusion protein containing the ectodomain of hTLR7 or hTLR2,
linked to the Fc portion of mouse IgG2a.
Murine TLR-Fc Protein Purification
mTLR9-Fc and mTLR2-Fc proteins were obtained and purified as described
in (Rutz et al., 2004).
SPR Biosensor Analysis
ODN binding of mTLR9-ect or mTLR2-ect was analyzed in a Biacore X device
(Biacore AB) on SA chips at 25C. In brief, the biotinylated ODN were diluted
to a final concentration of 100 nM in 50 mM MES, pH 6.5, supplemented
with 150 mM NaCl and 1 mM MgCl2 (which was also used as running buffer
in all SPR biosensor measurements), and bound at equimolar immobilization
levels (1700 RU for PD CpG-B ODN 1668 and PD non-CpG ODN AP1,
600 RU for C3-spacer, PD 20 deoxyribose, and PD ribose homopolymers)
to the SA in one of the two flow cells. The second flow cell served as a blank
control for the subtraction of nonspecific analyte binding and of bulk refractive
index background. For SPR monitoring of the mTLR9-ect or mTLR2-ect inter-
action to the surface immobilized ODNs, 45 ml of 100 nM recombinant protein
in running buffer was injected into the biosensor at a flow rate of 10 ml/min. Af-
ter a 300 s dissociation period, the biosensor chip was regenerated by two 5 ml
injections of a solution containing 50 mM NaOH and 1 M NaCl and extensive
re-equilibration in running buffer.
Competitive binding analyses were performed by 10 min pre-incubation of
200 nM mTLR9-ect with the PD or PS variants of 20 deoxyribose (20-mer),
non-CpG ODN AP-1 and IRS ODN 869 at concentrations of 0.01, 0.1, 1 and
10 mM and subsequent injection of the mixture over a PD CpG-B ODN 1668
coupled biosensor surface.
AlphaScreen TLR Binding Assay
The AlphaScreen (amplified luminescent-proximity homogeneous assay) was
set up as an association assay. TLR-ect-Fc protein was incubated with bioti-
nylated ligand in 50 mM HEPES, pH 6.5, 150 mM NaCl, 5 mM EDTA, 0.1%322 Immunity 28, 315–323, March 2008 ª2008 Elsevier Inc.BSA, and 0.01% Tween 20 for 60 min. Subsequently, protein-A-coated accep-
tor beads and streptavidin-coated donor beads (Alphascreen beads, Perkin
Elmer) were added from 53 stock concentrations. After 30 min incubation at
25C in the dark, samples in white 384-well plates (Proxiplate, Perkin Elmer)
were read with the Envision HT microplate reader (Perkin Elmer). Data were
analyzed by GraphPad Prism version 4.00 for Macintosh (GraphPad Software).
SUPPLEMENTAL DATA
Five figures are available at http://www.immunity.com/cgi/content/full/28/3/
315/DC1/.
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